Ulcerative Colitis

The results are consistent with the original analysis from 2019, where the treatment resulted in a statistically significant effect on fibrosis improvement.

There was also a greater likelihood of vaccine recommendation observed from pediatricians compared to other medical specialties.

Patients with Crohn’s disease subtype, females, pediatric-onset IBD, young adult patients with IBD, and patients with short-duration IBD were all at a higher risk for suicide.

There was no association found between ever using metformin and the risk of either IBD, Crohn’s disease, or ulcerative colitis.

There was an increased odds of liver injury per exposure-mixture quartile increase for organochlorine pesticides, PBDEs) perfluoroalkyl substances, and metals.

Both the incidence and prevalence of the liver disease were higher in men than they were in women.

The majority of patients in the phase 2 study met the primary efficacy endpoint of a greater than or equal to a 10% reduction in total stool output over the 6-week efficacy evaluation period.

The mean values of stool scale form also increased in the kombucha cohort, while the control group remained unchanged.

There were no negative safety signals in postnatal outcomes of exposed children in terms of growth, psychomotor development, and the risk of allergy, atopy, or infectious complications.

The approval represents the first and only specific interleukin-23 (IL-23) inhibitor for this patient population.

Azathioprine and 6-mercaptopurine therapeutic drug monitoring informed a management change in 61.9% of the patients with IBD.

Acute hepatitis of unknown etiology is not reportable in the US, making it difficult to understand whether recent levels are now reaching historic levels.

Dr. Gadani often suggests patients eat smaller meals and do not eat too close to bedtime.

Patients with anti-HBs also had higher APRI scores, FIB-4 scores, and liver stiffness values.

Dr. Akash B. Gadani said overall treatments for managing GERD are effective.

Patients with obesity who had bariatric surgery had lower rates of mortality compared to patients who did not have bariatric surgery.

In recent years more and more biologics have come on the market for the treatment of IBD.

In data presented at DDW, there was no evidence found showing biologics result in an increased risk of developing malignancies for patients with IBD and PSC.

The bioactive triterpenoid saponin was associated with edema in treated patients.

Investigators in a new multicenter study observed poor vaccine-induced serological responses in patients treated with infliximab or tofacitinib.

Patients who demonstrated high trough concentrations early on in treatment were more likely to achieve remission by weeks 14 or 52.

Subcutaneous administration of the gut-selective treatment was notably well-tolerated, safe, and cost-effective.

Significantly more patients treated with upadacitinib achieved clinical remission compared to patients treated with placebo.

Dr. Simonetto is involved in several studies using artificial intelligence.

The investigators will now move forward testing the 150 mg dosage of the treatment in a phase 3 trial.